Lamellar Ichthyosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Lamellar Ichthyosis Market Outlook
Thelansis’s “Lamellar Ichthyosis
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Lamellar Ichthyosis treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Lamellar
Ichthyosis Overview
Lamellar
ichthyosis (LI) is a genetically heterogeneous keratinization disorder
inherited in an autosomal recessive manner. It is classified as a subtype of
autosomal recessive congenital ichthyosis (ARCI), a spectrum of nonsyndromic
ichthyoses caused by genetic mutations in various genes. The disease course of
LI varies from mild to severe, with severe cases involving complications such
as ectropion, eclabium, scarring alopecia of the scalp and eyebrows, and palmar
and plantar hyperkeratosis. The presenting feature of LI in neonates is a
collodion membrane, which eventually dries and peels away, leaving behind a
brown, plate-like scale that covers the entire body. The underlying genetic
mutations that cause LI have been identified in various genes, including TGM1,
ALOX12B, ABCA12, and NIPAL4. Most mutations are found in the TGM1 gene, which
encodes transglutaminase 1, a protein forming the epidermal cornified cell
envelope. Patients with LI have an average life expectancy. However, skin
scaling can lead to complications such as obstruction of sweat glands,
resulting in thermoregulatory difficulties, and bacterial colonization in areas
of excessive scaling may lead to chronic ear infections. Other complications
include nail dystrophy, ectropion formation, and scarring alopecia. The
differential diagnosis of LI includes other forms of ichthyosis, recessive
X-linked ichthyosis, semi-dominant ichthyosis Vulgaris, and erythroderma. The
course of the disease is variable and may remain stable throughout life, with
periods of exacerbation. However, LI can significantly impact the quality of
life due to the altered physical appearance, symptoms, and limitations imposed
by the disease and its treatment.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment